What is HC Wainwright's Forecast for ONCY FY2027 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright upped their FY2027 earnings estimates for shares of Oncolytics Biotech in a research note issued to investors on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.08) for the year, up from their prior estimate of ($0.09). HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech's FY2028 earnings at $0.39 EPS.

ONCY has been the topic of a number of other research reports. Royal Bank of Canada cut their price objective on shares of Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating on the stock in a research report on Monday. Maxim Group cut their price objective on shares of Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating on the stock in a research report on Monday. Finally, Raymond James raised shares of Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th. Three research analysts have rated the stock with a buy rating, According to MarketBeat, Oncolytics Biotech presently has a consensus rating of "Buy" and a consensus target price of $4.00.

Oncolytics Biotech Price Performance

NASDAQ ONCY traded up $0.00 during trading on Thursday, reaching $0.63. 118,147 shares of the company's stock traded hands, compared to its average volume of 1,288,895. The company's 50 day simple moving average is $0.76 and its two-hundred day simple moving average is $0.92. Oncolytics Biotech has a 12-month low of $0.58 and a 12-month high of $1.53. The firm has a market cap of $53.44 million, a price-to-earnings ratio of -2.31 and a beta of 1.18.

Remove Ads

Institutional Trading of Oncolytics Biotech

Several large investors have recently bought and sold shares of ONCY. International Assets Investment Management LLC grew its position in Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock worth $186,000 after purchasing an additional 26,069 shares during the last quarter. Vantage Point Financial LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth approximately $27,000. Virtu Financial LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth approximately $90,000. National Bank of Canada FI lifted its stake in Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock valued at $60,000 after acquiring an additional 42,955 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Oncolytics Biotech by 59.6% during the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock valued at $61,000 after acquiring an additional 24,997 shares during the period. Hedge funds and other institutional investors own 6.82% of the company's stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.